Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy.

Biomaterials - 1 Apr 2010

Morishige Tomohiro, Yoshioka Yasuo, Inakura Hiroshi, Tanabe Aya, Yao Xinglei, Tsunoda Shin-ichi, Tsutsumi Yasuo, Mukai Yohei, Okada Naoki, Nakagawa Shinsaku

Abstract excerpt

The cytokine LIGHT activates various anti-tumor functions through its two receptors, lymphotoxin beta receptor (LTbetaR) and herpes virus entry mediator (HVEM), and is expected to be a promising candidate for cancer therapy. However, LIGHT is also trapped by decoy receptor 3 (DcR3), which is high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Mutation
Share to Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Recombinant Proteins

Share to Surface Plasmon Resonance

Source

Identifiers

PMID: 20117833
DOI: 10.1016/j.biomaterials.2010.01.022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20117833-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy.PMID 20117833Read ↗

Computational Design of a Highly-Specific HVEM-Based Inhibitor of LIGHT ProteinSemantic proximity Read ↗

Ribosome display: a potent display technology used for selecting and evolving specific binders with desired propertiesSemantic proximity Read ↗

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.Semantic proximity Read ↗

Design and Validation of the First-in-Class PROTACs for Targeted Degradation of the Immune Checkpoint LAG-3Semantic proximity Read ↗

Engineering light-controllable CAR T cells for cancer immunotherapySemantic proximity Read ↗

Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160.Semantic proximity Read ↗

Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.Semantic proximity Read ↗

Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability.Semantic proximity Read ↗

Structure-based rational design of a Toll-like receptor 4 (TLR4) decoy receptor with high binding affinity for a target protein.Semantic proximity Read ↗

Single-chain nanobody inhibition of Notch and avidity enhancement utilizing the β-pore forming toxin AerolysinSemantic proximity Read ↗

Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)Semantic proximity Read ↗

A photoregulated ligand for the nuclear import receptor karyopherin alpha.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.